Alumis
Alumis Inc is a clinical-stage biopharmaceutical enterprise headquartered in South San Francisco, California. The company focuses on the discovery, development, and commercialization of oral precision medicines designed to address severe autoimmune and inflammatory diseases. Its proprietary research and clinical pipeline targets specific molecular pathways to deliver targeted therapies for conditions such as plaque psoriasis and systemic lupus erythematosus. Principal revenue is currently earned through private capital financing arrangements, research grants, and development partnerships as the enterprise advances its clinical drug candidates. Alumis Inc is publicly listed on the Nasdaq Stock Market.
6 of the funds FundTelligence covers report a position in Alumis.
- Legal name
- Alumis Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 6
- Exposure themes
- Autoimmune diseases, Treatment, Women's Health
Funds holding Alumis
- DNB Fund Women's Health — DNB · 1.11 % (full portfolio disclosed, August 2026)
- JPM Global Healthcare Fund — JPM · 0.57 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, October 2026)